BUSINESS

Oryzon soars 22% in the stock market after announcing a settlement with the US National Cancer Institute.

[ad_1] MADRID, July 19 (EUROPA PRESS) – Oryzon Genomics is up nearly 22% in the stock market at the end of the session after it announced it has signed a collaborative research and development agreement (CRADA) with the United States’ National Cancer Institute (NCI) to continue clinical development of the LSD1 – Clinical-stage inhibitor, iadademstat, …

Oryzon soars 22% in the stock market after announcing a settlement with the US National Cancer Institute. Read More »

Exit mobile version